ArticleParasites & vectors2025
Catechin gallate triggers metabolomic and lipidomic alteration in Toxoplasma gondii.
Article in Parasites & vectors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lipidomic Profiling of Colonic Contents in Mice with AcuteMicroorganisms · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundToxoplasma gondii is a zoonotic parasite, the causative agent of toxoplasmosis, which has global importance owing to its significant socioeconomic, public health, and veterinary burdens. Toxoplasmosis is currently treated with a combination of pyrimethamine and sulfadiazine. These drugs have treatment failures and toxicity and are ineffective against the bradyzoite stage. Hence, there is a need for new inhibitors against T. gondii. Catechin gallate (CG) is a known antioxidant with demonstrated antiparasitic properties. However, little is known about its anti-Toxoplasma gondii activity and mechanism of action.
methodsHere, we assess the effect of CG on human telomerase reverse transcriptase immortalized foreskin fibroblast (hTERT) cells, cytotoxicity, and inhibitory activity of the RH-RFP (type I) strain of T. gondii tachyzoite. Inhibitory and cytotoxicity activities were measured by a fluorescent plate reader, and the data were analyzed using Graph Pad Prism software. In addition, to predict the possible mechanism of CG action, hTERT cells were cultured in a T25 flask and infected with RH-RFP parasites, followed by CG administration and incubation for 48 h. Parasites were quenched under ice, and the parasites were purified from host cells and extracted with chloroform-methanol. The extracts containing the lipids and metabolites were analyzed using liquid chromatography-mass spectrometry (LC-MS).
resultsTo address this research question, we tested the in vitro inhibitory activity of CG against parasite growth at 48 h and 72 h. The half-maximal inhibitory concentration (IC
conclusionsThe study showed that CG had inhibitory activity against T. gondii growth and caused metabolite and lipid alterations in T. gondii. This requires future studies on the enzymes associated with the biosynthesis of these metabolite/lipid pathways that are altered in these in vitro studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.